. Author manuscript; available in PMC: 2022 Sep 7.

Published in final edited form as: Am J Kidney Dis. 2019 Feb 21;74(1):47–55. doi: 10.1053/j.ajkd.2018.12.027

Table 3.

Multivariable Model for CKD at Baseline in Patients with Sickle Cell Disease

	HbSS/HbSβ⁰-Thalassemia (Severe genotypes)		HbSC/HbSβ⁺-Thalassemia (Mild genotypes)
	OR (95%CI)	P	OR (95%CI)	P
Hemoglobin, per 1-g/dL greater			0.63 (0.43, 0.93)	0.02
History of avascular necrosis	0.40 (0.16, 0.97)	0.04
ACEi/ARB therapy	6.1 (2.03, 18.29)	0.001

Results from age- and sex- adjusted multivariable logistic regression model

OR – odds ratio, CI – confidence interval; ACEi = Angiotensin-converting enzyme inhibitor, ARB = angiotensin receptor blocker.